ReviewAnalytical science advances2025
Emerging Biosensor Technologies for Stroke Biomarker Detection: A Comprehensive Overview.
Review in Analytical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation.Journal of clinical medicine · 2026Review
- Multifunctional synergistic action of metal-organic framework composites enhance the electrochemical detection sensitivity of dopamine.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026Article
- Plasma Metabolic Signature and Single-Cell Regulatory Network for Ischemic Stroke.Translational stroke research · 2026Article
- Nanomaterial-enhanced biosensors for traumatic brain injury biomarker detection: a review of analytical performance, machine learning integration, clinical validation, and point-of-care translation.Frontiers in neurology · 2026Review
- Emerging Biosensor Technologies for Stroke Biomarker Detection: A Comprehensive Overview.Analytical science advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke remains a leading cause of morbidity and mortality worldwide, necessitating the development of rapid and reliable diagnostic tools for early detection and management. This manuscript presents an overview of innovative biosensors designed for the detection of key stroke biomarkers, including N-terminal pro B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), D-dimer, cardiac troponins, S100B protein, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), matrix metalloproteinases (MMPs), interleukins and fibrinogen. We discuss the principles of operation, sensitivity, specificity and the technological advancements that have enabled the development of these biosensors, including electrochemical, optical and microfluidic platforms. The integration of nanomaterials and advanced signal amplification techniques has significantly enhanced the performance of these biosensors, allowing for the detection of biomarkers at low concentrations in complex biological samples. Furthermore, we explore the clinical implications of these biosensors in the context of stroke diagnosis, prognosis and monitoring, highlighting their potential to facilitate timely therapeutic interventions. By providing a comprehensive discussion on the current state of biosensor technology for stroke biomarker detection, this manuscript aims to underscore the importance of these tools in improving patient outcomes and advancing stroke research. Future directions for biosensor development and the challenges that remain in translating these technologies into clinical practice are also addressed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.